Share Name Share Symbol Market Type Share ISIN Share Description
Meon Cap. LSE:MC. London Ordinary Share GB0034270156 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p - - - - - - - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0.00

Meon Cap. Share Discussion Threads

Showing 51 to 74 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
02/7/2013
12:41
I can assure I had an email from Phil Jackson yesterday and things will be fine
northernlad
04/1/2006
18:00
New thread for Dermasalve Sciences (DRM)- http://www.advfn.com/cmn/fbb/thread.php3?id=10630979
jonwig
04/1/2006
09:11
johnjunks, my post #6: Assuming full consideration paid and PBT of £3.3m in 2007 that means Earnings = £3.3m X 0.7 = £2.31m = 231m pence. Discount that at 10%pa for 2 yrs gives discounted earnings 187m pence. Pay this over 95m shares (ie. max consideration paid) means eps about 2p in 2007. If PBT is at the bottom end (£1.65m) the discounted eps becomes about 1.6p. At the lower end, earnings = £1.65m * 0.7 * 0.9 * 0.9 = £0.94m, so eps = 94m ÷ 59m = 1.6p/sh At the upper end (£3.3m) earnings = £3.3m * 0.7 * 0.9 * 0.9 = £1.87m, so eps = 187m ÷ 95m = 2.0p/sh Happy to admit to any errors, but have checked. DRM doesn't seem to be recognised yet ...
jonwig
04/1/2006
08:56
FOR RELEASE 7.00AM 4 JANUARY 2006 DERMASALVE SCIENCES PLC ("Dermasalve" or "the Company") (A manufacturer and distributor of a range of skin healthcare and toiletry products specifically for dry and sensitive skin sufferers) Dermasalve Sciences starts trading on AIM Dealings are due to commence today in Dermasalve Sciences Plc, which produces a range of skin healthcare and toiletry products specifically for dry and sensitive skin sufferers. This follows the Company's successful reverse into Meon Capital Plc ("Meon"). Following a Placing of 6,227,262 ordinary shares at 11p and the completion of the reverse into Meon, a total of 59,709,076 Ordinary Shares are due to be admitted to trading on the Alternative Investment Market ("AIM") today, giving Dermasalve a market capitalisation at the Placing Price of ¿6.57 million. Corporate Synergy is the Nominated Adviser and Broker to the Company. Dr. Clive Morton OBE, the Chairman of Dermasalve, commented: In the recent months leading up to the reverse into Meon Capital and our flotation on AIM, we having been putting the infrastructure in place to develop Dermasalve into a leading brand targeted at people who suffer from dry and sensitive skin who are allergic or sensitive to alcohols and a number of other commonly used chemical agents in creams. We have recruited a highly experienced sales team to cover the whole of the UK market and we estimate that Dermasalve products will soon be available in approximately 75% of the independent chemists in the UK. Following the success of the reverse takeover of Meon Capital and the Placing, we now have the resources in place to commence actively marketing our product range. With this in mind, we have today appointed a highly experienced public relations consultancy which understands the markets in which we operate. We have also been working closely with our advertising agency and, from the start of February, we will be launching our first consumer advertising campaign to drive sales. We are currently working on a number of initiatives which will further enhance the Dermasalve brand and I look forward to informing our shareholders of our progress as the year develops. In the meantime, I believe that we have an exciting future ahead of us." Dermasalve Sciences Mark Randle (Chief Executive) 07765 258 973 Corporate Synergy Plc William Vandyk 020 7448 4400 Cubitt Consulting Brian Coleman Smith / Nia Thomas / Allison Reid 020 7367 5100 Mobile 07802 724 400 Background note: Dermasalve produces a range of lifestyle, healthcare and toiletry products specifically for dry and sensitive skin sufferers. The products are currently focussed on the UK's ¿440 million over-the-counter and prescription medicated skincare market. It was formed in July 2003 by three North East based entrepreneurs: Dr Mark Randle, Karl Watkin and Steven Katirai. It is estimated that over 15 per cent. of the UK population and 60 million people in Europe suffer from some form of dry or sensitive skin condition or complaint and the global skincare market was estimated to be worth $28 billion in 2002. The skin health and prescription dermatology market is growing at over 10 per cent. per annum, due to changing demographics, increased skin sensitivities and allergies and the increasing awareness of skin cancer and fungal infections in populations. Dermasalve's products are targeted at two principal market areas: * the retail sector: moisturising creams, sun care products and toiletries; and * the prescription dermatology sector: treatments of eczema and psoriasis. Dermasalve distributes its products through Sangers, the Northern Ireland based wholesaler, Lloyds chemists (over 1,100 shops around the UK) and AAH Pharmaceuticals, a national wholesaler. These distribution channels within the wholesale and retail pharmacy sector cover a significant proportion of the UK's pharmacy retail outlets. The Company also believes that the products can potentially be sold as prescribed products through the UK's 32,000 general medical practitioners and 60,000 nurse practitioners. DIRECTORS Dr. Clive Neil Morton, aged 62, Non-Executive Chairman Dr. Clive Morton has a twenty year record of achievement in revitalising public and private organisations. He is Chairman of Peterborough Hospitals NHS Trust, and a visiting professor at three British universities. Dr Morton was formerly a non-executive director of Hartlepool Water Plc and the London Underground PPP. Dr Morton is a current member of the DTI Partnership Panel. Dr. Mark Randle, aged 39, Chief Executive Officer Mark Randle is an experienced doctor in UK general practice. He was a founding director of Datatrial Ltd, a company that sells data capture products and services to the European and US pharmaceuticals market. Mark also designed and developed interactive healthcare web-based learning and administration tools to supplement continuous professional development for healthcare staff. He was a founding director of eMedit, a company that produces multi media content for the medical professions deliverable over the internet, which he built up to a team of 18 with external investment. After selling his business interests in 2002 he began to research into the causes and management options of dry and sensitive skin conditions, skin cancer and muscular skeletal pain, leading to the development of DermaSalve and the founding of Dermasalve. Philip Pattison FCMA, ACIB, MBA, aged 45, Finance Director Philip Pattison is a highly experienced finance and commercial leader, with experience in banking, retail, engineering and service sectors. Philip was the Global Risk and Commercial Finance Leader for General Electric - PII Pipeline Solutions. Karl Eric Watkin MBE, aged 49, Non-Executive Director Karl Watkin has 30 years international business experience and has, in recent years, concentrated on the development of technology companies, conceiving, developing and successfully floating both J2C Plc and D1 Oils Plc. Karl was awarded North East businessman of the year in 1992, UK export manager of the year in 1985 and an MBE in 1993 for services to UK exports. Karl is a founder director of Dermasalve. Graham Ashley, aged 58, Non-Executive Director Graham Ashley has over forty years experience in stockbroking and corporate finance and was later a founding director and shareholder of stockbroker Greig Middleton. He has advised on acquisitions and disposals and fundraising across a wide range of sectors and industries and is currently a consultant to Arbuthnot Securities Limited. END
barefoot1
04/1/2006
07:18
Barefoot: DRM - do you want to begin your new thread??? jojhnjunks2 - calculated in an earlier post, will have another look.
jonwig
03/1/2006
23:46
Happy New Year to you too and Prosperous Investing....been watching for a while and waiting....hoping to buy in at a decent price in the morning.....any ideas on the epic???? someone just found what could be it...DRM???
barefoot1
03/1/2006
23:32
Thanks for that Barefoot, you are on the ball. I dont know how you do it. Hope you had a happy New Year. Jonwig I dont see where you get earnings per share of 2p/ share. I have worked out that at an issue rice of 11p there will be approximatley 59mil shares in issue which at 3.3m = 5.59 p per share pre tax after tax = 4.36p (Say 22% tax)discount 10% per annum = 3.53p per share and 1.766p per share at the lower estimate which gives a guide price of 17.6 p to 35.3 on a PE of 10. If this share performs at the upper end of expectations then its worth a lot more than a PE of 10, time will tell.
jojhnjunks2
03/1/2006
11:24
FOR IMMEDIATE RELEASE 3 JANUARY 2005 MEON CAPITAL PLC to be renamed: DERMASALVE SCIENCES PLC RESULT OF EXTRAORDINARY GENERAL MEETING ALL RESOLUTIONS PASSED ACQUISITION APPOVED DEALINGS TO COMMENCE IN DERMASALVE SCIENCES ON 4 JANUARY 2006 At the Extraordinary General Meeting held in London today all the resolutions were passed and the change of name to Dermasalve Sciences Plc was approved. Dealings in the ordinary shares of Dermasalve Sciences Plc are expected to commence tomorrow, 4 January 2006. For further information: Meon Capital Plc David Massie (Chairman) 020 7389 1770 Dermasalve Sciences Mark Randle (Chief Executive) 07765 258 973 Corporate Synergy Plc William Vandyk 020 7448 4400 Cubitt Consulting Brian Coleman Smith / Nia Thomas / Allison Reid 020 7367 5100 Mobile 07802 724 400 Background note on Dermasalve Sciences Plc: Dermasalve produces a range of lifestyle, healthcare and toiletry products specifically for dry and sensitive skin sufferers. The products are currently focussed on the UK's ¿440 million over-the-counter and prescription medicated skincare market. It was formed in July 2003 by three North East based entrepreneurs: Dr Mark Randle, Karl Watkin and Steven Katirai. It is estimated that over 15 per cent. of the UK population and 60 million people in Europe suffer from some form of dry or sensitive skin condition or complaint and the global skincare market was estimated to be worth $28 billion in 2002. The skin health and prescription dermatology market is growing at over 10 per cent. per annum, due to changing demographics, increased skin sensitivities and allergies and the increasing awareness of skin cancer and fungal infections in populations. Dermasalve's products are targeted at two principal market areas: * the retail sector: moisturising creams, sun care products and toiletries; and * the prescription dermatology sector: treatments of eczema and psoriasis. Dermasalve distributes its products through Sangers, the Northern Ireland based wholesaler, Lloyds chemists (over 1,100 shops around the UK) and AAH Pharmaceuticals, a national wholesaler. These distribution channels within the wholesale and retail pharmacy sector cover a significant proportion of the UK's pharmacy retail outlets. The Company also believes that the products can potentially be sold as prescribed products through the UK's 32,000 general medical practitioners and 60,000 nurse practitioners. DIRECTORS Dr. Clive Neil Morton, aged 62, Non-Executive Chairman Dr. Clive Morton has a twenty year record of achievement in revitalising public and private organisations. He is Chairman of Peterborough Hospitals NHS Trust, and a visiting professor at three British universities. Dr Morton was formerly a non-executive director of Hartlepool Water Plc and the London Underground PPP. Dr Morton is a current member of the DTI Partnership Panel. Dr. Mark Randle, aged 39, Chief Executive Officer Mark Randle is an experienced doctor in UK general practice. He was a founding director of Datatrial Ltd, a company that sells data capture products and services to the European and US pharmaceuticals market. Mark also designed and developed interactive healthcare web-based learning and administration tools to supplement continuous professional development for healthcare staff. He was a founding director of eMedit, a company that produces multi media content for the medical professions deliverable over the internet, which he built up to a team of 18 with external investment. After selling his business interests in 2002 he began to research into the causes and management options of dry and sensitive skin conditions, skin cancer and muscular skeletal pain, leading to the development of DermaSalve and the founding of Dermasalve. Philip Pattison FCMA, ACIB, MBA, aged 45, Finance Director Philip Pattison is a highly experienced finance and commercial leader, with experience in banking, retail, engineering and service sectors. Philip was the Global Risk and Commercial Finance Leader for General Electric - PII Pipeline Solutions. Karl Eric Watkin MBE, aged 49, Non-Executive Director Karl Watkin has 30 years international business experience and has, in recent years, concentrated on the development of technology companies, conceiving, developing and successfully floating both J2C Plc and D1 Oils Plc. Karl was awarded North East businessman of the year in 1992, UK export manager of the year in 1985 and an MBE in 1993 for services to UK exports. Karl is a founder director of Dermasalve. Graham Ashley, aged 58, Non-Executive Director Graham Ashley has over forty years experience in stockbroking and corporate finance and was later a founding director and shareholder of stockbroker Greig Middleton. He has advised on acquisitions and disposals and fundraising across a wide range of sectors and industries and is currently a consultant to Arbuthnot Securities Limited. END
barefoot1
02/1/2006
15:43
If you go back to post #6, you'll see I've projected eps (2yr discount at 10%) of 2p if they reach the maximum consideration level, and 1.6p if they reach the minimum at which extra consideration above the minimum needs to be paid. So let's say eps of 1.6p. A share price of 16p gives a forward P/E of 10x, and might be a bit steep, given the fast growth needed. However, I'd still expect them to open nicely above 11.5p. If they drop below 10p, I'll have another look.
jonwig
02/1/2006
14:19
Thanx jonwig....from the rns and the price of meon ... am i right in thinking they will float at around 11.5p???
barefoot1
02/1/2006
14:02
Hi again Barefoot, There'll be an AIM admission RNS at about 8am, I think, which will tell you the EPIC. Best of luck if you buy - I'll follow your thread with interest, but don't intend jumping in until I've seen some results.
jonwig
02/1/2006
13:59
Dermasalve floating on the 4th....we'll have to create a new thread....anyone know the what the symbol will be.....will be ready and waiting to buy!!!!!
barefoot1
09/12/2005
00:57
Yoo can buy their products in LLoyds and major pharmacies!!
barefoot1
08/12/2005
11:11
Barefoot and others: personal opinions and reports are going to be pretty important in evaluating whether the T/O and profit figures are going to be met by 2007. My wife is a nurse in dermatology, but hadn't heard of them. She's going to ask around. Anyway, just for the record, here are some figures and projections from the RNS which may be worth preserving, if this becomes a serious investment proposition. current annualised 2007min 2007max T/O 20,760 36,000 3.9m 6.4m GrPf 14,021 24,000 2.65m 4.3m Admin 175,021 300,000 1m 1m PretaxPf(161,000)(276,000) 1.65m 3.3m The first column is for the 7 month period stated in the RNS. I've assumed admin costs of 1m for 2007, and a gross margin of 67.5%. The former may be too low, and the latter too high to be maintained - we'll see.
jonwig
07/12/2005
20:14
Saw you need to see a doctor if you look like that.... lol
insipiens
07/12/2005
18:54
looks like he needs some plink... plink... fizz!!!!
barefoot1
07/12/2005
18:39
I know someone who has used their dry skin cream and swears by it...they take steriods and have very thin skin...they knocked their leg about 8 months ago and the wound wouldn't heal...she started using the cream 3 weeks ago and it's nearly better now...pretty good advert!!!!
barefoot1
07/12/2005
08:08
Your right about Scott todd, but he did well with Darwen Capital and D1 has done well for me so on balance + what I know about products looks good to me! I will do more research and see what comes up.
jojhnjunks2
07/12/2005
07:52
Jon my wife would often say "if only the other bits were as big as them shovels stuck on the end of your arms".....my boy has eczema so i think we'll use him for the road test....;-))
jessica5
06/12/2005
19:39
Interesting linkage there, jojhnjunks2. But Scott Tod isn't exactly cashing in, is it? jessica, can you road test the product on your beautiful hands?
jonwig
06/12/2005
19:35
I have been watching this share because of Scott Todd but see that Karl Watkins of D1 is one of the founding directors:- Karl Eric Watkin MBE, aged 49, Non-Executive Director Karl Watkin has 30 years international business experience and has, in recent years, concentrated on the development of technology companies, conceiving, developing and successfully floating both J2C Plc and D1 Oils Plc. Karl was awarded North East businessman of the year in 1992, UK export manager of the year in 1985 and an MBE in 1993 for services to UK exports. Karl is a founder director of Dermasalve. D1 has been quite active and has been reported to be making a bid for Biofuels. I recon that with Massie & Watkins involved this is going to something special, partuicularily as they seem to be involved in finding a cure/treatment for eczema and psoriasis, two masssive markets. if there is anything in this, it could be as big as Yorke Pharma?
jojhnjunks2
06/12/2005
18:38
"News of a placing and acquisition helped to lift shares in Meon Capital 1p to 11.5p. The company said it would raise 685,000 pounds via a placing for working capital, as it announced plans to acquire the entire issued share capital of Dermasalve Sciences, a producer of a range of skin healthcare and toiletry products specifically for dry skin sufferers. The deal values Dermasalve at up to 8.2 million pounds, in a stock and loan notes deal. The skin care business must reach certain levels of profitability in order to qualify for the loan note payout, with pre-tax profits of 3.3 million pounds for the year to November 2007 just one of the targets. Still, the market welcomed the news, with the 11p placing price providing a useful cushion."
jessica5
06/12/2005
18:14
I hope the cream doesn't turn you green and make your head swell!
sawbones
06/12/2005
17:35
Thanks Barefoot. I was about to edit post #6 with the point that if they don't reach target profits we're left holding the pup!
jonwig
Chat Pages: 3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161204 12:19:42